Real-World Comparison of First-Line Treatment Adherence Between Single-Agent Ibrutinib and Acalabrutinib in Patients with Chronic Lymphocytic Leukemia.

Xiaoxiao Lu,Bruno Emond,Laura Morrison,Frederic Kinkead,Patrick Lefebvre,Marie-Hélène Lafeuille,Wasiulla Khan,Linda H Wu,Zaina P Qureshi,Ryan Jacobs

Patient preference and adherence（2023）

引用 0|浏览11

暂无评分

摘要

In this real-world analysis, CLL/SLL patients initiating 1L once-daily ibrutinib had >50% higher treatment adherence than those initiating twice-daily acalabrutinib during their LOT. Given the importance of sustained adherence for disease control in CLL/SLL, dosing frequency may be an important consideration for patients and physicians.

查看译文

关键词

adherence,acalabrutinib,treatment,real-world,first-line,single-agent

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要